ArticleHuman cell2019
miR-543 promoted the cell proliferation and invasion of nasopharyngeal carcinoma by targeting the JAM-A.
Article in Human cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Junctional Adhesion Molecule-A (JAM-A) Associates With High-Risk Disease in Multiple Myeloma Patients and a Structure-Based Rationally-Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo.European journal of haematology · 2026Article
- Hsa_circ_0028007 regulates the progression of nasopharyngeal carcinoma through the miR-1179/SQLE axis.Open medicine (Warsaw, Poland) · 2023Article
- Article
- Article
- The Long Non-Coding RNA HOXC-AS3 Promotes Glioma Progression by Sponging miR-216 to Regulate F11R Expression.Frontiers in oncology · 2022Article
- The F11 Receptor (F11R)/Junctional Adhesion Molecule-A (JAM-A) (F11R/JAM-A) in cancer progression.Molecular and cellular biochemistry · 2022Review
- Serum exosomal miR-34a as a potential biomarker for the diagnosis and prognostic of hepatocellular carcinoma.Journal of Cancer · 2022Article
- MicroRNA-384 inhibits nasopharyngeal carcinoma growth and metastasis via binding to Smad5 and suppressing the Wnt/β-catenin axis.Cytotechnology · 2021Article
- MiR-133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-β/Smad3 signaling pathway.Thoracic cancer · 2020Article
- Construction and analysis of miRNA-mRNA regulatory networks in the radioresistance of nasopharyngeal carcinoma.3 Biotech · 2020Article
- Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cell-Cell Interactions in Tumor Progression.Cancer research · 2020Review
- CircCTDP1 promotes nasopharyngeal carcinoma progression via a microRNA‑320b/HOXA10/TGFβ2 pathway.International journal of molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
MicroRNAs (miRNAs) are defined as small, non-coding RNAs that act as post-transcriptional regulators of gene expression. Dysfunction of miRNAs was involved in the initiation and progression of nasopharyngeal carcinoma (NPC). Here, we found that miR-543 was markedly overexpressed in NPC tissues and cell lines. Overexpression of miR-543 promoted the proliferation, cell cycle progression and invasion of NPC cells. Down-regulation of miR-543 inhibited the proliferation and induced apoptosis of NPC cells. Bioinformatics analysis suggested the junctional adhesion molecule A (JAM-A) as a potential target of miR-543. Furthermore, molecular study showed that the miR-543 bound the 3'-untranslated region (UTR) of JAM-A and decreased the expression of JAM-A in NPC cells. The expression of JAM-A in NPC tissues was decreased and negatively correlated with that of miR-543. Overexpression of JAM-A attenuated miR-543-induced proliferation of NPC cells. Collectively, these evidence indicated the important roles of miR-543/JAM-A signaling in the progression of NPC, highlighting the potential of miR-543 as a target in the treatment of NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.